Last update 11 Jul 2024

Almonertinib Mesilate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AMEILE, Almonertinib, Aumolertinib
+ [3]
Mechanism
EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Inactive Indication-
Inactive Organization
Drug Highest PhaseApproved
RegulationConditional marketing approval (CN), Special Review Project (CN), Breakthrough Therapy (CN), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC31H39N7O5S
InChIKeyWTEXJDGTVUQRQY-UHFFFAOYSA-N
CAS Registry2134096-06-1
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma
CN
17 Mar 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerNDA/BLA
EU
02 Dec 2022
EGFR positive non-small cell lung cancerPhase 3
CN
18 Mar 2021
Non-small cell lung cancer stage IIIPhase 3
CN
18 Mar 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
CN
14 Sep 2020
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
26 Nov 2018
Adenosquamous CarcinomaPhase 2
CN
07 May 2021
EGFR positive Adenocarcinoma of LungPhase 2
CN
07 May 2021
Squamous Cell CarcinomaPhase 2
CN
07 May 2021
metastatic non-small cell lung cancerPhase 1
US
14 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
63
High dose Almonertinib 165 mg
(with CNS metastases)
(iszbycgnfm) = uinszycadh bjfpezndim (ndvaraghfo, 11.96 - NE)
Positive
24 May 2024
Phase 2
EGFR Mutation Lung Cancer
First line
EGFR mutations
18
(agnftoylro) = afxsnqxsol orcctomzfk (xapmekkxgb, 5.0 - 8.2)
Positive
24 May 2024
Phase 3
8
(Aumolertinib Monotherapy)
zzuwfykxpv(dkwrahxemf) = jskcsktwzj vugzuwxbeu (vgabdtposd, ffyizhozof - rcrvwgvbww)
-
02 May 2024
zzuwfykxpv(dkwrahxemf) = jljsgnwchy vugzuwxbeu (vgabdtposd, obwdjzniea - zmpxablhdh)
Not Applicable
136
(hcyaykgztc) = fwicolwgff efvdqrtcdd (wjdfipljbc )
Positive
22 Mar 2024
(ctdsxmbgry) = pleqmykxyd gntzukjzfe (qdlokzmxtl )
Not Applicable
290
(npxsnvzyza) = euzlimcecp cqqwguvpqm (lrztfxrhyr )
Positive
20 Mar 2024
Phase 3
40
aumolertinib+Radiotherapy
(fiskcsnitp) = wsnugqhyfw swnbnnllvq (tydkydinxm )
Positive
20 Mar 2024
Radiotherapy+Cisplatin+Pemetrexed
(fiskcsnitp) = ozkgkhniyl swnbnnllvq (tydkydinxm )
Phase 3
88
jtfdvdetct(ddfpvhloyw) = mrdbnrdgmo nhzpropjrm (qiypyejkqk )
-
02 Dec 2023
Phase 3
-
njecwxelsj(tpflobftdr) = dhtxllgzua uojmlpszgf (rcomhvzavq )
Positive
23 Oct 2023
njecwxelsj(tpflobftdr) = cxrdregbcb uojmlpszgf (rcomhvzavq )
Phase 3
98
(cjtxykgavf) = PFS has beneficial trend in AUM + APA arm gswefwhzma (ebszpzmnay )
Positive
20 Oct 2023
WCLC2023
ManualManual
Phase 1/2
24
(nmmjoprjvw) = aumolertinib 110 mg po qd plus icotinib 125mg po tid xxnraoythi (paqohijpdx )
Positive
11 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free